Aragon & Janssen v. Hetero Labs: Erleada® Generic Blocked by Consent Judgment
Aragon Pharmaceuticals, Janssen Biotech, and the University of California secured a consent judgment against Hetero Labs and Hetero USA blocking generic apalutamide (Erleada®) from entering the US market until expiry of three asserted patents. The case resolved in just 131 days — well short of typical Hatch-Waxman trial timelines.
Hatch-Waxman consent judgment locks Hetero out of generic Erleada® market
Filed on 6 June 2024 in the District of New Jersey, this Hatch-Waxman ANDA infringement action was brought by Aragon Pharmaceuticals, Janssen Biotech, and The Regents of the University of California against Hetero Labs Ltd Unit V and Hetero USA, Inc. The plaintiffs asserted three patents — US9987261B2, US8802689B2, and US9388159B2 — covering apalutamide, the active pharmaceutical ingredient in Erleada®, Johnson & Johnson’s androgen receptor inhibitor approved for prostate cancer treatment under NDA No. 210951.
The case closed on 15 October 2024 via a consent judgment — a negotiated court order in which Hetero expressly admitted that the three asserted patents are valid, enforceable, and would be infringed by the commercial launch of its ANDA product. The court entered a permanent injunction prohibiting Hetero and its affiliates from manufacturing, selling, offering for sale, or importing the generic apalutamide product in the United States until the expiration of all three patents, including any patent term extensions, adjustments, and associated pediatric exclusivity periods. All claims and counterclaims were dismissed with prejudice.
Resolution in 131 days is notably swift for ANDA litigation, where trials are often scheduled near the end of the 30-month stay. The speed and terms — including Hetero’s express admission of validity and its waiver of appellate rights — suggest the parties reached a negotiated settlement incorporating a consent judgment, rather than Hetero contesting infringement on the merits. The public record does not disclose any authorised generic arrangement, licensing terms, or future market entry date granted to Hetero, leaving the precise commercial accommodation, if any, undisclosed.
Filing to Consent Judgment in 131 days
131 days — resolved before the standard 30-month Hatch-Waxman stay expired
Consent judgment and injunction: what the ruling means for both parties
Consent judgment = admission of validity and infringement
A consent judgment is a court-entered order reflecting a negotiated agreement between the parties. Critically here, Hetero did not merely settle — it expressly admitted that the three patents-in-suit are valid and enforceable, and that its ANDA product would infringe them. This is a stronger outcome than a standard dismissal and closes off future validity challenges by Hetero on these patents with respect to this product.
Dismissed with prejudiceInjunction protects Erleada® exclusivity until full patent term
Aragon, Janssen, and the UC Regents obtained a permanent injunction covering Hetero and all its affiliates. Critically, the injunction extends through patent term extensions, patent term adjustments, and any pediatric exclusivity periods — providing maximum available exclusivity. With Hetero’s admission of validity on record and appellate rights waived, this market protection is effectively final against this challenger.
Full exclusivity securedHetero waives appeal and admits infringement — market entry deferred
Hetero’s consent to the judgment forecloses re-entry to this litigation. It expressly waived all appellate rights and agreed to dismissal with prejudice of all its counterclaims. The public record does not disclose any authorised generic agreement or future entry date, meaning Hetero’s commercial upside from this ANDA filing, at least under these terms, appears deferred indefinitely pending patent expiry.
No market entry disclosedErleada® faces no near-term generic competition from this ANDA challenger
With Hetero enjoined and other ANDA filers not party to this action, Erleada® retains exclusivity against at least this generic challenger. The swift 131-day resolution and Hetero’s unconditional admission may signal that the patent portfolio — three granted US patents — was perceived as particularly strong. Competitors and other ANDA filers should note the breadth of the injunction, which expressly covers affiliates and all forms of US commercialisation.
Generic entry blockedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ARAGON PHARMACEUTICALS, INC. | Company | Pharmaceutical IP holders — holder of US9987261B2, US8802689B2, and US9388159B2 covering apalutamideSearch in Eureka ↗ |
| Co-Plaintiff | The Regents of the University of California | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Janssen Biotech, Inc. | Company | Search in Eureka ↗ |
| Defendant | Hetero Labs Ltd Unit V | Company | Indian generic pharmaceutical manufacturer filing ANDA for generic apalutamide (Erleada®)Search in Eureka ↗ |
| Co-Defendant | Hetero USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for ARAGON PHARMACEUTICALS, INC.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing ARAGON PHARMACEUTICALS, INC.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Hetero Labs Ltd Unit VSearch in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Hetero Labs Ltd Unit VSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is unusually explicit: Hetero not only agreed to an injunction but made an on-record admission that the three patents-in-suit are valid, enforceable, and would be infringed. This goes beyond a standard settlement dismissal. The with-prejudice dismissal of all claims and counterclaims, combined with an express waiver of appellate rights, leaves Hetero with no procedural avenue to re-open the dispute. The court retained jurisdiction solely for enforcement purposes, consistent with permanent injunction practice in Hatch-Waxman cases.
US9987261B2, US8802689B2 & US9388159B2 — Apalutamide prostate cancer therapy patents
The three patents-in-suit — US9987261B2, US8802689B2, and US9388159B2 — cover apalutamide, a next-generation androgen receptor inhibitor approved under NDA No. 210951 and marketed as Erleada® for the treatment of non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The patents originate from research at The Regents of the University of California and are exclusively licensed to Aragon Pharmaceuticals, subsequently acquired by Janssen (Johnson & Johnson). The patents collectively protect the compound, formulations, and therapeutic use — a layered portfolio strategy common in blockbuster oncology asset defence.
Erleada® is a high-value oncology asset in a competitive therapeutic class that includes enzalutamide (Xtandi) and darolutamide (Nubeqa). The breadth of the three-patent portfolio — spanning compound, synthesis, and use claims — creates a significant barrier for generic ANDA challengers. Hetero’s express admission of validity in this consent judgment reinforces the perceived strength of these patents and may influence how other ANDA filers assess the likelihood of successful invalidity challenges via IPR or litigation. For competitor R&D and IP teams, the portfolio warrants careful freedom-to-operate analysis before advancing apalutamide-adjacent compounds or formulations.
Should your R&D team run an FTO against US9987261B2, US8802689B2 & US9388159B2?
Any company developing androgen receptor inhibitors, prostate cancer therapies, or formulations containing apalutamide or structurally related compounds should treat these three patents as high-priority FTO targets. The injunction scope in this case covers not just the exact ANDA product but any product containing apalutamide as the sole active ingredient — signalling broad enforcement intent. Generic manufacturers, biosimilar developers, and combination-therapy researchers should assess claim scope before advancing to IND or ANDA filing stages.
PatSnap Eureka’s FTO Search Agent can map the full independent and dependent claim scope of US9987261B2, US8802689B2, and US9388159B2 against your candidate compound or formulation in minutes. Eureka identifies prior art landscapes, prosecution history estoppel, and related family members across jurisdictions — helping your IP and R&D teams identify white space or design-around strategies before costly late-stage development. Run your FTO analysis directly within Eureka to generate a defensible clearance report.
Run a freedom-to-operate analysis on US9987261B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases: apalutamide & androgen receptor inhibitors
Explore comparable Hatch-Waxman ANDA infringement cases in the oncology androgen receptor inhibitor space litigated in New Jersey District Court and similar venues.
What this case signals for the oncology small-molecule IP landscape
A swift consent judgment with express validity admissions sets a high bar for any ANDA challenger targeting Erleada® or similar androgen receptor inhibitor portfolios.
Express validity admissions in consent judgments raise the stakes for future challengers
Most ANDA settlements result in dismissals that leave validity unaddressed. Hetero’s express admission of validity and infringement in this consent judgment is atypical and strengthens the patent holder’s position against any subsequent challenger who might seek to rely on IPR or declaratory judgment proceedings to relitigate the same questions.
Speed of resolution suggests negotiated deal, not capitulation on merits alone
A 131-day resolution in Hatch-Waxman litigation is well below average. This pace typically signals a negotiated commercial arrangement — potentially including a future authorised generic licence or entry date not reflected in the public court record. IP teams monitoring Erleada® competition should track FDA Orange Book and ANDA docket filings for further clues.
ARAGON v Hetero — key questions answered
Under the consent judgment (Case No. 2:24-cv-06784, D.N.J.), Hetero Labs and Hetero USA expressly admitted that the three patents-in-suit (US9987261B2, US8802689B2, US9388159B2) are valid, enforceable, and would be infringed by the commercial launch of their generic apalutamide ANDA product in the United States. Hetero also waived all appellate rights.
Three patents were asserted: US9987261B2, US8802689B2, and US9388159B2 — all covering apalutamide, the active pharmaceutical ingredient in Erleada®. They collectively protect the compound, pharmaceutical compositions, and methods of use for prostate cancer treatment. The patents are tied to NDA No. 210951 and originate from research at The Regents of the University of California.
The injunction prohibits Hetero Labs, Hetero USA, and their affiliates from manufacturing, using, selling, offering for sale, or importing any generic apalutamide ANDA product in the United States until the expiration of all three patents-in-suit, including any patent term extensions, patent term adjustments, and any associated pediatric exclusivity periods.
The 131-day resolution is significantly faster than typical Hatch-Waxman litigation, which often proceeds to trial near the end of the 30-month stay. The speed and the nature of the consent judgment — including Hetero’s unconditional validity admission and appellate waiver — suggest a negotiated commercial resolution. The public record does not disclose any authorised generic terms or market entry dates that may have been separately agreed.
The consent judgment dismissed all claims and counterclaims with prejudice and Hetero waived all appellate rights — foreclosing further challenge by Hetero in this litigation. However, the consent judgment binds only the named parties. Third-party ANDA filers or entities pursuing IPR at the USPTO are not bound by Hetero’s admissions, though those admissions may carry persuasive weight in related proceedings.
PatSnap Eureka searches patents and litigation data to answer instantly.